Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine.

Carl D Marci^1,2, Kruti Joshi³, Stevan Geoffrey Severtson⁴, Janis L Breeze⁴, Manish K Jha⁵

¹OM1, Inc., Boston, MA, USA. cmarci@om1.com.

²Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. cmarci@om1.com.

³Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

⁴OM1, Inc., Boston, MA, USA.

⁵UT Southwestern Medical Center, Dallas, TX, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Treatment-resistant depression (TRD) is often characterized by inadequate response to ≥ 2 oral antidepressant treatments of adequate dose and duration during a major depressive episode (MDE). Esketamine nasal spray (ESK) was approved by the US Food and Drug Administration in 2019 for TRD in conjunction with an oral antidepressant under a Risk Evaluation and Mitigation Strategy ( https:…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.